197 related articles for article (PubMed ID: 38388539)
21. A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma.
Yan J; Zhou C; Guo K; Li Q; Wang Z
J Cell Biochem; 2019 Jan; 120(1):213-223. PubMed ID: 30206981
[TBL] [Abstract][Full Text] [Related]
22. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.
Jin C; Zhao JS; Huang XQ; Yang XZ; Niu FY; Lin JR; Ma L; Shi YX; Li XS; Jiang P; Gao S; Li F; Song Y
Hepatol Int; 2022 Oct; 16(5):1220-1233. PubMed ID: 35947245
[TBL] [Abstract][Full Text] [Related]
23. Novel application of the ferroptosis-related genes risk model associated with disulfidptosis in hepatocellular carcinoma prognosis and immune infiltration.
Wei J; Wang J; Chen X; Zhang L; Peng M
PeerJ; 2024; 12():e16819. PubMed ID: 38317842
[TBL] [Abstract][Full Text] [Related]
24. A disulfidptosis-related lncRNA index predicting prognosis and the tumor microenvironment in colorectal cancer.
Xiao L; Yin W; Chen X; Zhang X; Zhang C; Yu Z; Lü M
Sci Rep; 2023 Nov; 13(1):20135. PubMed ID: 37978247
[TBL] [Abstract][Full Text] [Related]
25. Identification of biomarkers of hepatocellular carcinoma gene prognosis based on the immune-related lncRNA signature of transcriptome data.
Ma A; Sun Y; Ogbodu RO; Xiao L; Deng H; Zhou H
Funct Integr Genomics; 2023 Mar; 23(2):104. PubMed ID: 36976410
[TBL] [Abstract][Full Text] [Related]
26. Combining a machine-learning derived 4-lncRNA signature with AFP and TNM stages in predicting early recurrence of hepatocellular carcinoma.
Fu Y; Si A; Wei X; Lin X; Ma Y; Qiu H; Guo Z; Pan Y; Zhang Y; Kong X; Li S; Shi Y; Wu H
BMC Genomics; 2023 Feb; 24(1):89. PubMed ID: 36849926
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive Analysis of Disulfidptosis-Related LncRNAs in Molecular Classification, Immune Microenvironment Characterization and Prognosis of Gastric Cancer.
Kang K; Li X; Peng Y; Zhou Y
Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137387
[TBL] [Abstract][Full Text] [Related]
28. Construction of a Ferroptosis-Related Nine-lncRNA Signature for Predicting Prognosis and Immune Response in Hepatocellular Carcinoma.
Xu Z; Peng B; Liang Q; Chen X; Cai Y; Zeng S; Gao K; Wang X; Yi Q; Gong Z; Yan Y
Front Immunol; 2021; 12():719175. PubMed ID: 34603293
[TBL] [Abstract][Full Text] [Related]
29. Identification of disulfidptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer.
Liang J; Wang X; Yang J; Sun P; Sun J; Cheng S; Liu J; Ren Z; Ren M
Front Immunol; 2023; 14():1198826. PubMed ID: 38035071
[TBL] [Abstract][Full Text] [Related]
30. Identification of an Oxidative Stress-Related LncRNA Signature for Predicting Prognosis and Chemotherapy in Patients With Hepatocellular Carcinoma.
Zhong Z; Xu M; Tan J
Pathol Oncol Res; 2022; 28():1610670. PubMed ID: 36277962
[No Abstract] [Full Text] [Related]
31. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
Pan G; Xie H; Xia Y
Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
[TBL] [Abstract][Full Text] [Related]
32. Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma.
Li R; Jin C; Zhao W; Liang R; Xiong H
BMC Gastroenterol; 2022 Nov; 22(1):450. PubMed ID: 36344926
[TBL] [Abstract][Full Text] [Related]
33. Construction of a ceRNA network and a genomic-clinicopathologic nomogram to predict survival for HBV-related HCC.
Huang K; Lu Z; Li L; Peng G; Zhou W; Ye Q
Hum Cell; 2021 Nov; 34(6):1830-1842. PubMed ID: 34487338
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive analysis of cuproptosis-related lncRNAs for prognostic significance and immune microenvironment characterization in hepatocellular carcinoma.
Li D; Jin S; Chen P; Zhang Y; Li Y; Zhong C; Fan X; Lin H
Front Immunol; 2022; 13():991604. PubMed ID: 36685508
[TBL] [Abstract][Full Text] [Related]
35. A Novel Cholesterol Metabolism-Related lncRNA Signature Predicts the Prognosis of Patients with Hepatocellular Carcinoma and Their Response to Immunotherapy.
Lei H; Xiang T; Zhu H; Hu X
Front Biosci (Landmark Ed); 2024 Mar; 29(3):129. PubMed ID: 38538256
[TBL] [Abstract][Full Text] [Related]
36. A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma.
Wang Z; Pan L; Guo D; Luo X; Tang J; Yang W; Zhang Y; Luo A; Gu Y; Pan Y
Cancer Med; 2021 Jun; 10(11):3808-3821. PubMed ID: 33934539
[TBL] [Abstract][Full Text] [Related]
37. Long non-coding RNA-based signature for predicting prognosis of hepatocellular carcinoma.
Cao J; Wu L; Lei X; Shi K; Shi L; Shi Y
Bioengineered; 2021 Dec; 12(1):673-681. PubMed ID: 33622186
[TBL] [Abstract][Full Text] [Related]
38. Preliminary findings on the development of a predictive model for BLCA based on disulfidptosis-associated IncRNAs signature.
Tang C; Fan Y; Zhu S
BMC Urol; 2024 Mar; 24(1):69. PubMed ID: 38532369
[TBL] [Abstract][Full Text] [Related]
39. Cuproptosis-Related LncRNA Signature for Predicting Prognosis of Hepatocellular Carcinoma: A Comprehensive Analysis.
Chen Q; Sun T; Wang G; Zhang M; Zhu Y; Shi X; Ding Z
Dis Markers; 2022; 2022():3265212. PubMed ID: 36452343
[TBL] [Abstract][Full Text] [Related]
40. Development and validation of a robust immune-related risk signature for hepatocellular carcinoma.
Liu Z; Jiao D; Liu L; Zhou X; Yao Y; Li Z; Li J; Chen J; Lei Q; Han X
Medicine (Baltimore); 2021 Mar; 100(10):e24683. PubMed ID: 33725827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
